The role of uric acid and allopurinol therapy in cardiovascular disease

1. Freedman DS, Williamson DF, Gunter EW et al. Relation of serum uric acid to mortality and ischemic heart disease The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995; 141(7): 637–644.

2. Strasak A, Ruttmann E, Brant L et al. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. Clin Chem 2008; 54(2): 273–284.

3. Watanabe S, Kang DH, Feng L et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40(3): 355–360.

4. Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol 2014; 26(2): 186–191.

5. Adamopoulos D, Vlassopoulos C, Seitanides B et al. The relationship of sex steroids to uric acid levels in plasma and urine. Acta Endocrinol (Copenh) 1977; 85(1): 198–208.

6. Choi HK, Atkinson K, Karlson EW et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004; 350(11): 1093–1103.

7. Drum DE, Goldman PA, Jankowski CB. Elevation of serum uric acid as a clue to alcohol abuse. Arch Intern Med 1981; 141(4): 477–479.

8. Faller J, Fox IH. Ethanol-induced hyperuricemia: evidence for increased urate production by activation of adenine nucleotide turnover. N Engl J Med. 1982; 307(26): 1598–1602.

9. Choi HK, Curhan G. Beer, liquor, and wine consumption and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2004; 51(6): 1023–1029.

10. Choi HK, Curhan G. Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey. Arthritis Rheum 2007; 57(5): 816–821.

11. Miller A, Adeli K. Dietary fructose and the metabolic syndrome. Curr Opin Gastroenterol 2008; 24(2): 204–209.

12. Mirrakhimov AE, Ali AM, Khan M et al. Tumor lysis syndrome in solid tumors: an up to date review of the literature. Rare Tumors 2014; 6(2): 5389.

13. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. American College of Physicians; American Physiological Society. Ann Intern Med 2005; 143(7): 499–516.

14. Marangella M. Uric acid elimination in the urine. Contrib Nephrol 2005; 147: 132–148.

15. Johnson RJ, Sánchez-Lozada LG, Mazzali M et al. What are the key arguments against uric acid as a true risk factor for hypertension? Hypertension 2013; 61(5): 948–951.

16. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med 2012; 125(7): 679–687.

17. Kim S, De Vera M, Choi H. Gout and mortality. Clin Exp Rheumatol 2008; 26(5 Suppl 51): S115-S119.

18. Campion EW, Glynn RJ, Delabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987; 82(3): 421–426.

19. Kim KY, Schumacher HR, Hunsche E et al. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003; 25(6): 1593–1617.

20. Lawrence RC, Felson DT, Helmick CG et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II. Arthritis Rheum 2008; 58(1): 26–35.

21. Richette P, Bardin T Gout. Lancet 2010; 375(9711): 318–328.

22. Brook RA, Forsythe A, Smeeding JE et al. Chronic gout: epidemiology, disease progression, treatment and disease burden. Curr Med Res Opin 2010; 26(12): 2813–2821.

23. Rho YH, Zhu Y, Choi HK. The epidemiology of uric acid and fructose. Semin Nephrol 2011; 31(5): 410–419.

24. Grayson PC, Kim SY, LaValley M et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011; 63(1): 102–110.

25. Kim SY, Guevara JP, Kim KM et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010; 62(2): 170–180.

26. Huang H, Huang B, Li Y et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail 2014; 16(1): 15–24.

27. Kim SY, Guevara JP, Kim KM et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2009; 61(7): 885–892.

28. Culleton BF, Larson MG, Kannel WB et al. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131(1): 7–13.

29. Kanbay M, Segal M, Afsar B et al. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart 2013; 99(11): 759–766. Dostupné z DOI: <http//dx.doi.org/10.1136/heartjnl-2012–302535>.

30. Chang HY, Tung CW, Lee PH et al. Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population. Am J Med Sci 2010; 339(6): 509–515.

31. Xu Y, Zhu J, Gao L et al. Hyperuricemia as an independent predictor of vascular complications and mortality in type 2 diabetes patients: a meta-analysis. PloS one 2013; 8(10): e78206. Dostupné z DOI: <http://doi: 10.1371/journal.pone.0078206>.

32. Perez-Pozo S, Schold J, Nakagawa T et al. Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. Int J Obes (Lond) 2010; 34(3): 454–461.

33. Liese AD, Hense HW, Löwel H et al. Association of Serum Uric Acid with All-Cause and Cardiovascular Disease Mortality and Incident Myocardial Infarction in the MONICA Augsburg Cohort. Epidemiology 1999; 10(4): 391–397.

34. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971–1992. JAMA 2000; 283(18): 2404–2410.

35. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359(17): 1811–1821.

36. Wu X, Muzny DM, Lee CC et al. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992; 34(1): 78–84.

37. Johnson RJ, Andrews P. Fructose, uricase, and the Back-to-Africa hypothesis. Evolutionary Anthropology: Issues, News, and Reviews 2010; 19(6): 250–257. Dostupné z DOI: <http://dx.doi.org/10.1002/evan.20266>.

38. Soltani Z, Rasheed K, Kapusta DR et al. Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal? Curr Hypertens Rep 2013; 15(3): 175–181.

39. Johnson RJ, Kang DH, Feig D et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41(6): 1183–1190.

40. Nieto FJ, Iribarren C, Gross MD et al. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 2000; 148(1): 131–139.

41. Ames BN, Cathcart R, Schwiers E et al. Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981; 78(11): 6858–6862.

42. Davies K, Sevanian A, Muakkassah-Kelly S et al. Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J 1986; 235(3): 747–754.

43. Reyes AJ, Leary WP. The increase in serum uric acid induced by diuretics could be beneficial to cardiovascular prognosis in hypertension: a hypothesis. J Hypertens 2003; 21(9): 1775–1777.

44. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981–2997. Erratum in: JAMA 2004; 291(18): 2196. JAMA 2003; 289(2): 178.

45. Sautin YY, Nakagawa T, Zharikov S et al. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007; 293(2): C584-C596. Erratum in Am J Physiol Cell Physiol 2010; 299(3): C726.

46. Corry DB, Eslami P, Yamamoto K et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008; 26(2): 269–275.

47. Sánchez-Lozada LG, Lanaspa MA, Cristóbal-García M et al. Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol 2012; 121(3–4): e71-e78.

48. Yu MA, Sanchez-Lozada LG, Johnson RJ et al. Oxidative stress with an activation of the renin–angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 2010; 28(6): 1234–1242.

49. Sánchez-Lozada LG, Soto V, Tapia E et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol 2008; 295(4): F1134-F1141.

50. Hershfield MS, Roberts LJ, Ganson NJ et al. Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc Natl Acad Sci USA 2010; 107(32): 14351–13456.

51. Yiginer O, Ozcelik F, Inanc T et al. Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome. Clin Res Cardiol 2008; 97(5): 334–340.

52. Cappola TP, Kass DA, Nelson GS et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001; 104(20): 2407–2411.

53. Doehner W, Schoene N, Rauchhaus M et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure results from 2 placebo-controlled studies. Circulation 2002; 105(22): 2619–2624.

54. George J, Carr E, Davies J et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114(23): 2508–2516.

55. Martinon F, Pétrilli V, Mayor A et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440(7081): 237–241.

56. Kang DH, Park SK, Lee IK et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16(12): 3553–3562.

57. Kanellis J, Watanabe S, Li JH et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003; 41(6): 1287–1293.

58. Ruggiero C, Cherubini A, Ble A et al. Uric acid and inflammatory markers. Eur Heart J 2006; 27(10): 1174–1181.

59. Leyva F, Anker S, Godsland I et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998; 19(12): 1814–1822.

60. Rock KL, Kataoka H, Lai JJ. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol 2013; 9(1): 13–23.

61. Khosla UM, Zharikov S, Finch JL et al. Hyperuricemia induces endothelial dysfunction. Kidney international 2005; 67: 1739–1742.

62. Choi YJ, Yoon Y, Lee KY et al. Uric acid induced endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. FASEB J 2014; 28(7): 3197–3204.

63. Kanbay M, Huddam B, Azak A et al. A randomized study of allopurinol on endothelial function and estimated glomelular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 2011; 6(8): 1887–1894.

64. Butler R, Morris AD, Belch JJ et al. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000; 35(3): 746–751.

65. Guthikonda S, Sinkey C, Barenz T et al. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation 2003; 107(3): 416–421.

66. El Solh A, Saliba R, Bosinski T et al. Allopurinol improves endothelial function in sleep apnoea: a randomised controlled study. Eur Respir J 2006; 27(5): 997–1002.

67. Dogan A, Yarlioglues M, Kaya MG et al. Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. Blood pressure 2011; 20(3): 182–187.

68. Meléndez-Ramírez G, Pérez-Méndez O, López-Osorio C et al. Effect of the treatment with allopurinol on the endothelial function in patients with hyperuricemia. Endocr Res 2012; 37(1): 1–6.

69. Yelken B, Caliskan Y, Gorgulu N et al. Reduction of uric acid levels with allopurinol treatment improves endothelial function in patients with chronic kidney disease. Clin Nephrol 2012; 77(4): 275–282.

70. Kao MP, Ang DS, Gandy SJ et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 2011; 22(7): 1382–1389.

71. Farquharson CA, Butler R, Hill A et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106(2): 221–226.

72. Mazzali M, Hughes J, Kim YG et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38(5): 1101–1106.

73. Eräranta A, Kurra V, Tahvanainen AM et al. Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency. J Hypertens 2008; 26(8): 1661–1668.

74. Saito I, Saruta T, Kondo K et al. Serum uric acid and the renin-angiotensin system in hypertension. J Am Geriatr Soc 1978; 26(6): 241–247.

75. Perlstein TS, Gumieniak O, Hopkins PN et al. Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int 2004; 66(4): 1465–1470.

76. Mene P, Punzo G. Uric acid: bystander or culprit in hypertension and progressive renal disease? J Hypertens 2008; 26(11): 2085–2092.

77. Mazzali M, Kanellis J, Han L et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002; 282(6): F991-F997.

78. Sanchez-Lozada LG, Tapia E, Santamaria J et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005; 67(1): 237–247.

79. Perlstein TS, Gumieniak O, Williams GH et al. Uric acid and the development of hypertension the normative aging study. Hypertension 2006; 48(6): 1031–1036.

80. Leite M. Uric acid and fibrinogen: age-modulated relationships with blood pressure components. J Hum Hypertens 2011; 25(8): 476–483.

81. Krishnan E, Kwoh CK, Schumacher HR et al. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007; 49(2): 298–303.

82. Mellen PB, Bleyer AJ, Erlinger TP et al. Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension 2006; 48(6): 1037–1042.

83. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 2011; 63(10): 3136–3141.

84. Niskanen LK, Laaksonen DE, Nyyssönen K et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004; 164(14): 1546–1551.

85. Meisinger C, Koenig W, Baumert J et al. Uric Acid Levels Are Associated With All-Cause and Cardiovascular Disease Mortality Independent of Systemic Inflammation in Men From the General Population The MONICA/KORA Cohort Study. Arterioscler Thromb Vasc Biol 2008; 28(6): 1186–1192.

86. Chen JH, Chuang SY, Chen HJ et al. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: A chinese cohort study. Arthritis Rheum 2009; 61(2): 225–232.

87. Kuo CF, See LC, Yu KH et al. Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology (Oxford) 2013; 52(1): 127–134.

88. Zhao G, Huang L, Song M et al. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. Atherosclerosis 2013; 231(1): 61–68.

89. Murrell G, Rapeport W. Clinical pharmacokinetics of allopurinol. Clin Pharmacokinet 1986; 11(5): 343–353.

90. Day RO, Graham GG, Hicks M et al. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet 2007; 46(8): 623–644.

91. Khanna D, Fitzgerald JD, Khanna PP et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64(10): 1431–1446.

92. Sivera F, Andrés M, Carmona L et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 2014; 73(2): 328–335.

93. Milurit, souhrn údajů o přípravku. Zdroj: SÚKL. Datum revize: 17. 9. 2014. Dostupné z WWW: <http://www.sukl.cz/modules/medication/detail.php?code=0119773&tab=info>.

94. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum 1986; 29(1): 82–87.

95. Halevy S, Ghislain PD, Mockenhaupt M et al. EuroSCAR Study Group. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58(1): 25–32.

96. Lee H, Ariyasinghe J, Thirumoorthy T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction? Singapore Med J 2008; 49(5): 384–387.

97. Arellano F, Sacristán JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993; 27(3): 337–343.

98. Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol 2002; 14(3): 281–286.

99. Lupton GP, Odom RB. The allopurinol hypersensitivity syndrome. J Am Acad Dermatol 1979; 1(4): 365–374.

100. Pluim H, Van Deuren M, Wetzels J. The allopurinol hypersensitivity syndrome. Neth J Med 1998; 52(3): 107–110.

101. McInnes G, Lawson D, Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis 1981; 40(3): 245–249.

102. Elasy T, Kaminsky D, Tracy M et al. Allopurinol hypersensitivity syndrome revisited. West J Med 1995; 162(4): 360.

103. Stamp LK, Taylor WJ, Jones PB et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheu. 2012; 64(8): 2529–2536.

104. Vinik O, Wechalekar MD, Falzon L et al. Treatment of asymptomatic hyperuricemia for the prevention of gouty arthritis, renal disease, and cardiovascular events: a systematic literature review. J Rheumatol Suppl 2014; 92: 70–74. Dostupné z DOI: <http://dx.doi.org/10.3899/jrheum.140465>.

105. Kanbay M, Ozkara A, Selcoki Y et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007; 39(4): 1227–1233.

106. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300(8): 924–932.

107. Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension 2012; 60(5): 1148–1156. Dostupné z DOI: <http://dx.doi.org//10.1161/HYPERTENSIONAHA.112.196980>.

108. Agarwal V, Hans N, Messerli FH. Effect of Allopurinol on Blood Pressure: A Systematic Review and Meta-Analysis. J Clin Hypertens (Greenwich) 2013; 15(6): 435–442.

109. Assadi F. Allopurinol enhances the blood pressure lowering effect of enalapril in children with hyperuricemic essential hypertension. J Nephrol 2014; 27(1): 51–56.

110. Higgins P, Walters M, Murray H et al. Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial. Heart 2014; 100(14): 1085–1092. Dostupné z DOI: <http://dx.doi.org/10.1136/heartjnl-2014–305683>.

111. Beattie CJ, Fulton RL, Higgins P et al. Allopurinol initiation and change in blood pressure in older adults with hypertension. Hypertension 2014; 64(5): 1102–1107.

112. Gois PHF, Souza ERM. Pharmacotherapy for hyperuricemia in hypertensive patients. Cochrane Database Syst Rev 2013; 1:CD008652. Dostupné z DOI. <http://dx.doi.org/10.1002/14651858.CD008652.pub2>.

113. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34(28): 2159–2219. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/eht151>.

114. Krishnan E. Gout and the risk for incident heart failure and systolic dysfunction. BMJ open 2012; 2(1): e000282.

115. Ekundayo OJ, Dell’Italia LJ, Sanders PW et al. Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study. Int J Cardiol 2010; 142(3): 279–287.

116. Anker SD, Doehner W, Rauchhaus M et al. Uric acid and survival in chronic heart failure validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107(15): 1991–1997.

117. Pascual Figal DA, Hurtado Martinez JA, Redondo B et al. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail 2007; 9(5): 518–524.

118. Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M et al. Hyperuricemia predicts adverse outcomes in patients with heart failure. Int J Cardiol 2011; 151(2): 143–147.

119. Tamariz L, Harzand A, Palacio A et al. Uric Acid as a Predictor of All-Cause Mortality in Heart Failure: A Meta-Analysis. Congest Heart Fail 2011; 17(1): 25–30.

120. Málek F, Ošťádal P, Pařenica J et al. Uric acid, allopurinol therapy, and mortality in patients with acute heart failure – results of the Acute HEart FAilure Database registry. J Crit Care 2012; 27(6): 737.

121. Hare JM, Johnson RJ. Uric Acid Predicts Clinical Outcomes in Heart Failure Insights Regarding the Role of Xanthine Oxidase and Uric Acid in Disease Pathophysiology. Circulation 2003; 107(15): 1951–1953.

122. Leyva F, Anker S, Swan J et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997; 18(5): 858–865.

123. Ekelund UE, Harrison RW, Shokek O et al. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res 1999; 85(5): 437–445.

124. Ukai T, Cheng CP, Tachibana H et al. Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure. Circulation 2001; 103(5): 750–755.

125. Stull LB, Leppo MK, Szweda L et al. Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res 2004; 95(10): 1005–1011.

126. Gavin AD, Struthers AD. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart 2005; 91(6): 749–753.

127. Struthers AD, Donnan PT, Lindsay P et al. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002; 87(3): 229–234.

128. Gotsman I, Keren A, Lotan C et al. Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival. J Card Fail 2012; 18(9): 694–701.

129. Ogino K, Kato M, Furuse Y et al. Uric acid lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled cross-over preliminary study. Circ Heart Fail 2010; 3(1): 73–81. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCHEARTFAILURE.109.868604>.

130. Thanassoulis G, Brophy JM, Richard H et al. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med 2010; 170(15): 1358–1364.

131. Hare JM, Mangal B, Brown J et al. Impact of oxypurinol in patients with symptomatic heart failure: results of the OPT-CHF study. J Am Coll Cardiol 2008; 51(24): 2301–2309.

132. George J, Struthers A. The OPT-CHF (Oxypurinol Therapy for Congestive Heart Failure) trial: a question of dose. J Am Coll Cardiol 2009; 53(25): 2405.

133. Givertz MM, Mann DL, Lee KL et al. Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients Design and Rationale of the EXACT-HF Study. Circ Heart Fail 2013; 6(4): 862–868.

134. McMurray JJ, Adamopoulos S, Anker SD et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14(8): 803–869. Erratum in Eur J Heart Fail 2013; 15(3): 361–362.

135. Levy WC, Mozaffarian D, Linker DT et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006; 113(11): 1424–1433.

136. Ky B, French B, Levy WC et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail 2012; 5(2): 183–190.

137. Bickel C, Rupprecht HJ, Blankenberg S et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002; 89(1): 12–17.

138. Høieggen A, Alderman MH, Kjeldsen SE et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65(3): 1041–1049.

139. Palmer TM, Nordestgaard BG, Benn M et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ 2013; 347: f4262. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.f4262>.

140. Wannamethee SG, Shaper AG Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart 1997; 78(2): 147–153.

141. De Luca G, Secco G, Santagostino M et al. Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr Metab Cardiovasc Dis 2012; 22(5): 426–433.

142. Wheeler JG, Juzwishin KD, Eiriksdottir G et al. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med 2005; 2(3): e76.

143. Noman A, Ang DS, Ogston S et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 2010; 375(9732): 2161–2167.

144. Rentoukas E, Tsarouhas K, Tsitsimpikou C et al. The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol 2010; 145(2): 257–258.

145. Rashid MA, William-Olsson G. Influence of allopurinol on cardiac complications in open heart operations. Ann Thorac Surg 1991; 52(1): 127–130.

146. Johnson WD, Kayser KL, Brenowitz JB et al. A randomized controlled trial of allopurinol in coronary bypass surgery. Am Heart J 1991; 121(1 Pt 1): 20–24.

147. Coghlan J, Flitter W, Clutton S et al. Allopurinol pretreatment improves postoperative recovery and reduces lipid peroxidation in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 1994; 107(1): 248–256.

148. Sisto T, Paajanen H, Metsä-Ketelä T et al. Pretreatment with antioxidants and allopurinol diminishes cardiac onset events in coronary artery bypass grafting. Ann Thorac Surg 1995; 59(6): 1519–1523.

149. Movahed A, Nair K, Ashavaid T et al. Free radical generation and the role of allopurinol as a cardioprotective agent during coronary artery bypass grafting surgery. Can J Cardiol 1996; 12(2): 138–144.

150. Talwar S, Sandeep JA, Choudhary SK et al. Effect of preoperative administration of allopurinol in patients undergoing surgery for valvular heart diseases. Eur J Cardiothorac Surg 2010; 38(1): 86–90.

151. Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34(38): 2949–3003.